Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JTK-853 is a novel, non-nucleoside inhibitor of Hepatitis C Virus (HCV) polymerase. It also displays effective antiviral activity in HCV replicon cells (EC50s: 0.38 and 0.035 μM in genotype 1a H77 and 1b Con1 strains, respectively).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 15,000 | 8-10周 | ||
50 mg | ¥ 19,800 | 8-10周 | ||
100 mg | ¥ 25,500 | 8-10周 |
产品描述 | JTK-853 is a novel, non-nucleoside inhibitor of Hepatitis C Virus (HCV) polymerase. It also displays effective antiviral activity in HCV replicon cells (EC50s: 0.38 and 0.035 μM in genotype 1a H77 and 1b Con1 strains, respectively). |
靶点活性 | HCV 1a H77:(EC50)0.38 μM, HCV 1b Con1:0.035 μM |
体外活性 | JTK-853 inhibits the drug-resistant colony formation in the genotype 1a replicon cells, and the numbers of JTK-853-resistant colonies are much lower than those of GS-9190-resistant colonies for both genotypes. When JTK-853 is incubated with the replicon cells for 48 h, it shows antiviral activity against genotype 1a H77 and 1b Con1 replicon cells (EC90: 6.5±0.5 and 0.34±0.05 μM, respectively). In 2-week culture, JTK-853(at 10 μM) causes apparent Huh-7.5 cell death[1]. |
分子量 | 704.64 |
分子式 | C28H23F7N6O4S2 |
CAS No. | 954389-09-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JTK-853 954389-09-4 Others JTK853 JTK 853 Inhibitor inhibitor inhibit